An analysis of data from the decades-long Nurses’ Health Study revealed that women who ate a one-ounce serving of nuts – any kind of nuts – two or more times a week had a 35 percent lower risk of pancreatic cancer than women who abstained from them. That’s a significant and encouraging piece of news for a field that has had far too little.
The 36th annual San Antonio Breast Cancer Symposium, which ran from Dec. 10-14, brought news of significant advances against a disease that strikes more than 230,000 women and 2,000 men in the United States each year. The more than 1,000 research papers presented by thousands of scientists and physicians ranged from laboratory explorations of the basic biology of the disease to studies that may change the treatment for patients with a variety of breast cancer subtypes. Here are summaries of the findings of several high-profile studies:
As the holiday season fills with family gatherings, travel and potluck parties, it is important to be extra attentive to avoiding germs. In addition to getting a flu shot, there are a number of other ways to prevent illness. Candace Hsieh, RN, CIC, of Dana-Farber’s Center for Patient Safety, offers some tips for staying healthy and reducing the chance for infection:
While some people claim dairy products can prevent cancer, others argue that dairy could actually increase the cancer risk. There are also concerns that dairy can potentially spur growth in hormone-sensitive cancers, including some forms of ovarian and breast cancer. Is there a relationship between dairy and cancer? We consulted with the Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) Nutrition Department to find out.
Approximately 173,000 people in the United States are living with Hodgkin lymphoma, or are in remission. Less common than non-Hodgkin lymphoma, Hodgkin lymphoma (sometimes referred to as Hodgkin’s lymphoma) is a malignancy of B lymphocytes, an important cell in the immune system. This malignant B cell is known as the Reed-Sternberg cell. Arnold Freedman, MD, clinical director of the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program, answers some questions about the disease:
Lymphoma: How do we treat it? Where are future therapies headed? On Wednesday, Dec. 18, Ann LaCasce, MD, of the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program will answer your questions about lymphoma care in a live video webchat. The 45-minute chat starts at 1 p.m. EST and will air live on Dana-Farber’s YouTube page. LaCasce will discuss current treatment options as well as future therapies for lymphoma. If you have a question for Dr. LaCasce, email firstname.lastname@example.org. You can also submit questions by sending us a Tweet @DanaFarber using the hashtag #DFCIWebchat. Bookmark the webchat video page and …
When Tara Shuman was diagnosed with breast cancer in August 2012, blogging was not the first thing that came to mind. “I put together an email to my friends and family to tell them about my diagnosis, and I realized when writing the email that it was very therapeutic,” Shuman says.
Current lymphoma therapies are a far cry from the mustard gas used more than 50 years ago. More treatment options, including ones that may be more effective and less toxic, are being studied in ongoing clinical trials. “Clinical trials really are the future of lymphoma treatment,” says Ann LaCasce, MD, a medical oncologist in the Adult Lymphoma Program at Dana-Farber/Brigham and Women’s Cancer Center.
One month after undergoing a mammogram live on “Good Morning America,” ABC reporter Amy Robach announced Monday she has been diagnosed with breast cancer and will undergo a double mastectomy later this week. At 40-years old, Robach is among a population of younger women with breast cancer. According to the American Cancer Society, about 5 percent of all breast cancer cases in the United States occur in women age 40 and younger.